Last updated: September 24, 2026
Brimonidine tartrate and carbachol are being developed as a fixed-combination ophthalmic treatment for presbyopia, principally under the investigational name BRIMOCHOL PF by Visus Therapeutics. The product has no FDA approval, commercial revenue, Orange Book listing, or established market share. Its financial value depends on successful Phase 3 development, FDA acceptance of an NDA, differentiation from pilocarpine products, and the durability of its patent and exclusivity position.
The combination targets the large presbyopia market but remains a high-risk development asset rather than a marketed pharmaceutical product.
What is brimonidine tartrate and carbachol used for?
Brimonidine tartrate and carbachol are being developed as an ophthalmic therapy for presbyopia, the age-related loss of near-vision accommodation.
Brimonidine is an alpha-2 adrenergic agonist used commercially in glaucoma and ocular-hypertension products. Carbachol is a cholinergic agonist used in ophthalmic surgery and historically in glaucoma treatment. In combination, the active ingredients are intended to produce pharmacologic miosis and improve near visual acuity by increasing the eye's depth of focus.
The development rationale differs from conventional reading glasses and from purely accommodative drug approaches:
| Attribute |
Brimonidine tartrate plus carbachol |
Pilocarpine products |
Reading glasses |
| Intended use |
Pharmacologic presbyopia correction |
Pharmacologic presbyopia correction |
Optical correction |
| Mechanism |
Miosis and increased depth of focus |
Miosis and ciliary-muscle stimulation |
External focusing aid |
| Administration |
Ophthalmic drops |
Ophthalmic drops |
As needed |
| FDA-approved presbyopia status |
No |
Vuity approved; other products may be investigational |
Not applicable |
| Key commercial risk |
Clinical and regulatory execution |
Adverse effects, dosing frequency and limited duration |
Low cost and high familiarity |
Visus has described BRIMOCHOL PF as a preservative-free formulation designed to provide near-vision improvement while limiting some tolerability concerns associated with cholinergic therapy. The product remains investigational. [1]
What is the FDA regulatory status of brimonidine tartrate and carbachol?
BRIMOCHOL PF does not have FDA approval as of the latest publicly available development information. It is not listed in the FDA Orange Book as an approved fixed-dose combination for presbyopia. [2]
The regulatory path is expected to require:
- Completion of adequate and well-controlled Phase 3 trials.
- Demonstration of clinically meaningful near-vision improvement.
- Evidence supporting duration of effect and dosing frequency.
- Characterization of ocular and systemic safety.
- Chemistry, manufacturing and controls data for the preservative-free formulation.
- Submission and FDA review of a New Drug Application.
The relevant regulatory pathway is a conventional NDA under Section 505(b)(1) of the Federal Food, Drug, and Cosmetic Act unless the sponsor establishes a different legal basis. Because the fixed combination is not an approved product, generic substitution through an abbreviated new drug application is not immediately available.
Is brimonidine tartrate and carbachol listed in the Orange Book?
No approved fixed-combination product containing brimonidine tartrate and carbachol is identified in the Orange Book. Separate products containing brimonidine or carbachol do not create an Orange Book listing for the investigational combination.
If approved, the sponsor could seek listing of patents covering the drug product, formulation, method of use and potentially manufacturing processes. Orange Book-listed patents would create a framework for future Paragraph IV challenges by generic applicants.
What clinical development has BRIMOCHOL PF completed?
Visus Therapeutics initiated late-stage studies evaluating BRIMOCHOL PF in adults with presbyopia. Public clinical-trial records identify Phase 3 studies designed to assess near-vision improvement and safety. [3]
The main clinical value drivers are:
- Improvement in distance-corrected near visual acuity.
- Duration of effect across the intended dosing interval.
- Preservation of functional distance vision.
- Reduction in headache, brow ache, accommodative spasm and dim-light visual complaints.
- Tolerability under repeated dosing.
- Commercially practical dosing, preferably once or twice daily.
The product competes clinically against pilocarpine-based presbyopia treatments. Pilocarpine has a longer regulatory history but can produce headache, blurred distance vision, dim vision and difficulty adapting to variable pupil size. A brimonidine-carbachol combination would need to show a meaningful benefit in duration, tolerability or patient convenience to support premium pricing.
When could brimonidine tartrate and carbachol lose exclusivity?
There is no confirmed FDA approval date or public commercial exclusivity date for BRIMOCHOL PF. As a result, a definitive loss-of-exclusivity date cannot be calculated.
Potential regulatory exclusivity would depend on the eventual approval pathway:
| Exclusivity category |
Potential availability |
| New chemical entity exclusivity |
Unlikely to apply if both active ingredients have prior approval and established regulatory histories |
| New clinical investigation exclusivity |
Potentially available if the approval relies on sponsor-conducted essential clinical studies |
| Orphan-drug exclusivity |
Unlikely because presbyopia affects a large population |
| Pediatric exclusivity |
Possible only if FDA requirements are satisfied |
| Patent term restoration |
Potentially available for qualifying patents, subject to statutory limits |
| Formulation or method patents |
Potentially material if valid and enforceable |
The commercial protection period will probably depend more on patents covering the fixed combination, concentration ratios, preservative-free formulation, dosing regimen and presbyopia indication than on regulatory exclusivity alone.
What patents protect brimonidine tartrate and carbachol?
The publicly available commercial record does not establish a complete, verified patent estate for BRIMOCHOL PF. The likely protection categories are:
Fixed-combination composition patents
These patents may cover the combination of brimonidine or a pharmaceutically acceptable salt with carbachol at defined concentration ranges. They are important because a generic applicant could attempt to design around a narrow concentration claim.
Ophthalmic formulation patents
Formulation claims may cover:
- Preservative-free delivery.
- pH and osmolality ranges.
- Buffer systems.
- Surfactants or viscosity agents.
- Container-closure systems.
- Stability during multi-dose use.
- Reduced ocular irritation.
Formulation patents can delay generic entry when the active ingredients are old but the delivery system is new.
Method-of-use patents
Potential claims may cover treating presbyopia with the combination, dosing once or twice daily, improving near visual acuity, or reducing the need for corrective lenses.
Method-of-use patents can be challenged through Paragraph IV certifications, although generic applicants may attempt a skinny-label strategy that excludes the patented indication.
Manufacturing patents
The manufacturing barrier is likely lower than for biologics because both active ingredients are small molecules. The main technical barriers may involve control of degradation, uniformity of the preservative-free solution, container compatibility and batch-to-batch stability.
How large is the market for pharmacologic presbyopia treatment?
The commercial market is supported by the aging population and the large number of adults who experience presbyopia. Most patients currently use reading glasses, multifocal lenses, contact lenses or surgical procedures. Prescription eye drops represent a new category rather than a direct replacement for an established prescription-drug market.
The market has three layers:
| Market layer |
Commercial characteristics |
| Total presbyopia population |
Very large, global and predominantly untreated with prescription drops |
| Addressable prescription-drop population |
Adults willing to pay for temporary spectacle-free near vision |
| Obtainable market |
Limited by efficacy, side effects, dosing convenience, insurance coverage and consumer awareness |
Vuity, a pilocarpine ophthalmic solution, became the first FDA-approved prescription eye drop specifically indicated for presbyopia in 2021. [4] Its approval validated the regulatory category but also established a competitive benchmark for efficacy and tolerability.
The market is likely to be predominantly cash-pay. Presbyopia correction is often treated as an elective convenience rather than a medically necessary therapy, reducing reimbursement support and increasing sensitivity to out-of-pocket price.
How does brimonidine-carbacol compare with Vuity?
| Factor |
Brimonidine tartrate plus carbachol |
Vuity |
| Active ingredient |
Fixed combination |
Pilocarpine hydrochloride |
| Sponsor |
Visus Therapeutics, based on public development disclosures |
AbbVie |
| Regulatory status |
Investigational |
FDA approved for presbyopia |
| Mechanistic approach |
Combined alpha-2 adrenergic and cholinergic activity |
Cholinergic activity |
| Commercial position |
Potential differentiated entrant |
First approved prescription product in category |
| Main development issue |
Proof of superior benefit-risk profile |
Expanding adoption and managing tolerability |
| Generic risk |
None before approval and patent expiry |
Future Paragraph IV and patent challenges |
The combination could gain a niche if it provides longer duration or better tolerability than pilocarpine alone. If its efficacy is similar and its safety profile is not materially better, the commercial rationale becomes weaker because physicians and patients already have an approved option.
What is the financial trajectory of the brimonidine-carbacol program?
Visus Therapeutics is a private company, and publicly available information does not provide a complete audited income statement, product revenue history or program-level cash-flow statement. The product therefore has no reported commercial revenue.
Its financial trajectory can be divided into four stages:
Development stage
Cash use is driven by clinical trials, formulation work, regulatory preparation and manufacturing scale-up. Phase 3 ophthalmology trials can require substantial capital because they involve multiple sites, specialized visual-acuity testing and large patient populations.
Regulatory stage
An NDA submission would increase spending on regulatory operations, validation batches, quality systems, pharmacovigilance planning and commercial readiness. The program would remain cash consumptive until approval.
Launch stage
The commercial model would likely require:
- Ophthalmology sales representatives.
- Direct-to-consumer education.
- Sample distribution.
- Patient-support programs.
- Specialty pharmacy or retail-pharmacy access.
- Payer and employer-benefit discussions.
- Post-marketing safety monitoring.
Because presbyopia drops are likely to be largely cash-pay, marketing expense and patient acquisition cost could be high relative to net price.
Post-launch stage
Revenue growth would depend on prescription persistence and repeat use. A product used intermittently may generate lower annual revenue per patient than a chronic glaucoma medicine, even if its launch price is high.
A simple commercial sensitivity framework is:
| Scenario |
Commercial assumptions |
Financial implication |
| Low case |
Limited efficacy differentiation, high out-of-pocket price, weak persistence |
Narrow specialty market and slow payback |
| Base case |
Regulatory approval, modest clinical advantage and focused ophthalmology adoption |
Moderate prescription growth with substantial marketing expense |
| High case |
Clear duration or tolerability advantage, strong consumer demand and broad access |
Rapid category expansion and partnership or acquisition interest |
No reliable public basis supports a precise revenue forecast. Any forecast should be modeled from patient starts, refill persistence, net price, launch timing and sales-and-marketing expense rather than from the total presbyopia population.
Which companies are competing in the presbyopia drug market?
The principal competitive reference points include:
- AbbVie, through Vuity.
- Orasis Pharmaceuticals, through investigational presbyopia drops.
- Lenz Therapeutics, through investigational aceclidine-based products.
- Visus Therapeutics, through BRIMOCHOL PF.
- Companies developing extended-depth-of-focus contact lenses, intraocular lenses and surgical presbyopia procedures.
The competitive threat is broader than prescription eye drops. Over-the-counter reading glasses remain inexpensive, immediately available and effective. Multifocal contact lenses and lens-based surgery also compete for patients seeking reduced dependence on spectacles.
What generic launch risks exist?
There is no immediate generic launch risk because the combination is not approved. The risk profile would change after approval.
Potential entry routes include:
- Paragraph IV challenge to Orange Book-listed patents.
- Paragraph III certification with delayed entry until patent expiry.
- Section viii carve-out of patented presbyopia indications.
- Design-around of concentration, formulation or dosing claims.
- Competing 505(b)(2) products using one or both active ingredients.
Small-molecule ingredients create a higher long-term generic risk than biologic products. The principal defense would be a layered patent estate with claims covering the commercial formulation and clinically important dosing regimen.
What licensing deals and litigation affect the product?
No major public licensing transaction or patent litigation involving an FDA-approved brimonidine-car-bachol product has established commercial rights for the combination. Visus Therapeutics remains the principal publicly identified developer of BRIMOCHOL PF.
There is no confirmed Orange Book litigation or Paragraph IV litigation for the investigational combination. Any future dispute would likely concern formulation patents, method-of-use claims, ownership of clinical data, or licensing rights.
How strong is the commercial position of brimonidine tartrate and carbachol?
The asset has a large theoretical market but a moderate-to-high execution risk profile.
| Strength |
Risk |
| Large presbyopia population |
No FDA approval |
| Existing familiarity with both active ingredients |
Unproven fixed-combination benefit |
| Potential differentiation from pilocarpine |
Side-effect and tolerability concerns |
| Small-molecule manufacturing pathway |
Likely out-of-pocket payment |
| Potential formulation and method-of-use protection |
Low barrier to future generic chemistry |
| Established ophthalmology prescriber base |
Competition from Vuity and new entrants |
The most important value inflection points are Phase 3 efficacy, duration of effect, safety findings, NDA acceptance, FDA approval and evidence of prescription persistence after launch.
Key Takeaways
- Brimonidine tartrate and carbachol are being developed as BRIMOCHOL PF for pharmacologic treatment of presbyopia.
- The product is investigational and has no FDA approval, Orange Book listing or commercial revenue.
- Visus Therapeutics is the principal publicly identified developer.
- The combination competes primarily with Vuity and other investigational presbyopia drops.
- Its commercial rationale depends on better duration, tolerability or patient experience than pilocarpine.
- No reliable public data establishes product-level revenue, valuation or audited financial performance.
- Patent protection is likely to focus on the fixed combination, preservative-free formulation, dosing regimen and presbyopia method of use.
- Generic entry is not an immediate risk but could become material after approval because both active ingredients are small molecules.
- The program's financial trajectory remains development-stage and cash consumptive until regulatory approval and commercialization.
FAQs
Is brimonidine tartrate and carbachol approved for presbyopia?
No. The fixed combination is investigational and is not listed as an FDA-approved presbyopia treatment.
What is the brand name for brimonidine tartrate and carbachol?
The investigational product has been publicly identified as BRIMOCHOL PF, developed by Visus Therapeutics.
Can pharmacies substitute brimonidine and carbachol for Vuity?
No. The combination is not an FDA-approved generic equivalent to Vuity. Pharmacy substitution requires an approved product and applicable state substitution rules.
Is BRIMOCHOL PF a biologic or small-molecule drug?
It is a small-molecule ophthalmic combination. Its active ingredients are brimonidine tartrate and carbachol.
What would make the product commercially successful?
The strongest commercial drivers would be FDA approval, longer duration than pilocarpine, acceptable ocular tolerability, convenient dosing, strong patient persistence and a price that supports cash-pay adoption.
References
-
Visus Therapeutics. (n.d.). BRIMOCHOL PF development program. Visus Therapeutics.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.
-
National Library of Medicine. (n.d.). ClinicalTrials.gov records for BRIMOCHOL PF and presbyopia clinical studies. ClinicalTrials.gov.
-
U.S. Food and Drug Administration. (2021). FDA approves first prescription eye drop to improve near vision in adults with age-related blurry near vision. FDA.
